Sagimet Biosciences to Present Mechanism of Action Data for its FASN Inhibitors at the Society for Investigative Dermatology in Chicago
Sagimet Biosciences announced preclinical data demonstrating the potential of fatty acid synthase (FASN) inhibitors to reduce sebum production, a key factor in acne. This supports their upcoming Phase 3 clinical trial of denifanstat for moderate to severe acne in the U.S., planned to initiate in the second half of 2026. The data will be presented a…